<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02689284</url>
  </required_header>
  <id_info>
    <org_study_id>CP-MGAH22-05</org_study_id>
    <nct_id>NCT02689284</nct_id>
  </id_info>
  <brief_title>Combination Margetuximab and Pembrolizumab for Advanced, Metastatic HER2(+) Gastric or Gastroesophageal Junction Cancer</brief_title>
  <official_title>A Phase 1b/2, Open Label, Dose Escalation Study of Margetuximab in Combination With Pembrolizumab in Patients With Relapsed/Refractory Advanced HER2+ Gastroesophageal Junction or Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MacroGenics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>MacroGenics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This main purpose of this clinical study is to learn about the safety and activity of
      margetuximab and pembrolizumab combination treatment in patients with HER2+ gastric and
      gastroesophageal junction cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Detailed Description: Both margetuximab and pembrolizumab are monoclonal antibodies used in
      combination to treat HER2+ gastric and gastroesophageal junction cancer. This study has two
      parts: Dose Escalation and Dose Expansion. The Dose Escalation phase of the study will
      evaluate safety of escalating doses of the combination treatment. The Dose Expansion phase
      will evaluate safety and activity of the combination in patients with gastric or
      gastroesophageal cancer once the final dose and schedule are defined. In addition, a cohort
      of patients with HER2+ 3+ gastric cancer patients will be enrolled in the Dose Expansion
      Phase.

      Patients may receive margetuximab monotherapy for an additional 2 years beyond the 2 years of
      margetuximab/pembrolizumab combination therapy.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the recommended expansion phase dose of margetuximab in combination with pembrolizumab</measure>
    <time_frame>9 months</time_frame>
    <description>Characterize maximum tolerated dose (MTD) or maximum administered dose (MAD) (if no MTD is defined) of margetuximab when administered in combination with pembrolizumab</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-Tumor Activity</measure>
    <time_frame>12 months</time_frame>
    <description>Investigate the preliminary anti-tumor activity as measured by response duration of margetuximab when administered in combination with pembrolizumab, using both conventional Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 and immune-related response criteria (irRC).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-Tumor Activity</measure>
    <time_frame>12 Months</time_frame>
    <description>Investigate the preliminary anti-tumor activity, as measured by objective response rate (ORR) of margetuximab when administered in combination with pembrolizumab, using conventional Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 and immune-related response criteria (irRC).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>24 Months</time_frame>
    <description>To investigate the preliminary effect of the combination treatment on OS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>24 Months</time_frame>
    <description>To investigate the preliminary effect of the combination treatment on PFS</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">95</enrollment>
  <condition>Gastric Cancer</condition>
  <condition>Stomach Cancer</condition>
  <condition>Esophageal Cancer</condition>
  <arm_group>
    <arm_group_label>Margetuximab plus pembrolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>margetuximab administered in combination with pembrolizumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Margetuximab plus pembrolizumab</intervention_name>
    <description>margetuximab in combination with pembrolizumab; combination treatment is administered once every 21-day cycle</description>
    <arm_group_label>Margetuximab plus pembrolizumab</arm_group_label>
    <other_name>Keytruda</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed written informed consent.

          2. Age ≥ 18 years old (or minimum age based upon local regulations)

          3. Unresectable locally advanced or metastatic histologically proven HER2+
             gastroesophageal junction (GEJ) or gastric cancer. Gastric Cancer Expansion Phase will
             include only gastric cancer patients with 3+ HER2 positivity.

          4. HER2+ as 3+ (as defined in AJCC staging manual 8th edition) by IHC or in-situ
             hybridation (ISH) amplified.

          5. Have received prior treatment with trastuzumab.

          6. Have received treatment with at least one or more lines of cytotoxic chemotherapy in
             the metastatic setting.

          7. Resolution of chemotherapy, immunotherapy or radiation-related toxicities.

          8. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

          9. Life expectancy ≥ 12 weeks.

         10. Measurable disease as per RECIST 1.1 criteria.

        Exclusion Criteria:

          1. Patients with symptomatic central nervous system (CNS) metastases.

          2. Patients with any history of known or suspected autoimmune disease with the specific
             exceptions of vitiligo, atopic dermatitis, or psoriasis not requiring systemic
             treatment.

          3. History of prior allogeneic bone marrow, stem-cell or solid organ transplantation.

          4. Treatment with any systemic anti-neoplastic therapy, or investigational therapy within
             the 3 weeks prior to the initiation of study drug.

          5. Treatment with radiation therapy within 3 weeks prior to the initiation of study drug
             administration.

          6. Treatment with corticosteroids (≥10 mg per day prednisone or equivalent) or other
             immune suppressive drugs within the 14 days prior to the initiation of study drug
             administration.

          7. History of clinically-significant cardiovascular disease.

          8. Clinically-significant pulmonary compromise, including a requirement for supplemental
             oxygen use to maintain adequate oxygenation.

          9. History of (non-infectious) pneumonitis that required steroids or presence of active
             pneumonitis

         10. Clinically-significant gastrointestinal disorders, such as perforation,
             gastrointestinal bleeding, or diverticulitis.

         11. Evidence of active viral, bacterial, or systemic fungal infection.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Minori Rosales, M.D., PhD</last_name>
    <role>Study Director</role>
    <affiliation>MacroGenics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yale School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgetown University-Lombardi Comprehensive Cancer Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute/Harvard University Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Cancer Institute</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Juravinski Cancer Centre - McMaster University</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V5C2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGill University Health Centre</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4A3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyungbuk National University Hospital</name>
      <address>
        <city>Daegu</city>
        <zip>41404</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gachon University Gil Medical Center</name>
      <address>
        <city>Incheon</city>
        <zip>21565</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chonbuk National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>54907</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea University Anam Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Centre</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National University Cancer Institute</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Raffles Hospital</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tri-Service General Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Korea, Republic of</country>
    <country>Singapore</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>January 27, 2016</study_first_submitted>
  <study_first_submitted_qc>February 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 23, 2016</study_first_posted>
  <last_update_submitted>July 8, 2020</last_update_submitted>
  <last_update_submitted_qc>July 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Stomach Cancer</keyword>
  <keyword>Gastroesophageal Junction</keyword>
  <keyword>Gastric Cancer</keyword>
  <keyword>Cancer of the Stomach</keyword>
  <keyword>Cancer of Stomach</keyword>
  <keyword>Stomach</keyword>
  <keyword>Pembrolizumab</keyword>
  <keyword>Keytruda</keyword>
  <keyword>HER2+</keyword>
  <keyword>GEJ</keyword>
  <keyword>HER2 positive</keyword>
  <keyword>Metastatic</keyword>
  <keyword>Margetuximab</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Trastuzumab</keyword>
  <keyword>Human epidermal growth factor receptor 2</keyword>
  <keyword>Human epidermal growth factor receptor 2-positive</keyword>
  <keyword>gastroesophageal junction cancer</keyword>
  <keyword>Pembro</keyword>
  <keyword>PD-L1</keyword>
  <keyword>PD-1</keyword>
  <keyword>PD</keyword>
  <keyword>Tumor</keyword>
  <keyword>Cancer</keyword>
  <keyword>KEYNOTE MK3475-PN197</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

